Low level Her2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1553-1560

  Minner, Sarah ^a   Jessen, Birte ^a   Stiedenroth, Lars ^a   Burandt, Eike ^a   Köllermann, Jens ^a   Mirlacher, Martina ^a   Erbersdobler, Andreas ^a   Eichelberg, Christian ^a   Fisch, Margit ^a   Brümmendorf, Tim Henrik ^a   Bokemeyer, Carsten ^a   Simon, Ronald ^a   Steuber, Thomas ^a   Graefen, Markus ^a   Huland, Hartwig ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION; TUMOR CELL; TUMOR RECURRENCE;

AGED; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77649108628     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2546     Document Type: Article

References (52)

1. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-62.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15: 2894-904.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
6. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23: 2162-71.
7. Sanchez KM, Sweeney CJ, Mass R, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer 2002;95:1650-5.
8. Ibrahim GK, MacDonald JA, Kerns BJ, et al. Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. Surg Oncol 1992;1:151-5.
9. McCann A, Dervan PA, Johnston PA, et al. c-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990;65:88-92.
10. Ware JL, Maygarden SJ, Koontz WW, Jr., et al. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 1991;22:254-8.
11. Mellon K, Thompson S, Charlton RG, et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992;147:496-9.
12. Visakorpi T, Kallioniemi OP, Koivula T, et al. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 1992;5:643-8.
13. Kuhn EJ, Kurnot RA, Sesterhenn IA, et al. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993; 150:1427-33.
14. Ross JS, Nazeer T, Church K, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993;72:3020-8.
15. Cohen RJ, Cooper K, Haffejee Z, et al. Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology 1995;27:229-32.
16. Gu K, Mes-Masson AM, Gauthier J, et al. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 1996;99:185-9.
17. Lyne JC, Melhem MF, Finley GG, et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997;3:21-30.
18. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79:2162-70.
19. Reese DM, Small EJ, Magrane G, et al. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001;116:234-9.
20. Jorda M, Morales A, Ghorab Z, et al. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 2002;168: 1412-4.
21. Edwards J, Mukherjee R, Munro AF, et al. HER2 and COX2 expression in human prostate cancer. Eur J Cancer 2004;40:50-5.
22. Montironi R, Mazzucchelli R, Barbisan F, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006;37:1137-44.
23. Liu HL, Gandour-Edwards R, Lara PN, Jr., et al. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J 2001;7:395-403.
24. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59:803-6.
25. Schlomm T, Borgermann C, Heinzer H, et al. Role of lymphnode dissection in prostate cancer. Urologe A 2008;48:37-45.
26. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13:6579-84.
27. Fleischmann A, Schlomm T, Huland H, et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008;14:7838-42.
28. Erbersdobler A, Fritz H, Schnoger S, et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002;41:40-6.
29. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
30. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
31. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
32. Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
33. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
34. Shi Y, Brands FH, Chatterjee S, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166:1514-9.
35. Savinainen KJ, Saramaki OR, Linja MJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002;160:339-45.
36. Isharwal S, Miller MC, Epstein JI, et al. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer 2008;123:2636-43.
37. Fossa A, Lilleby W, Fossa SD, et al. Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 2002;99:100-5.
38. Morote J, de Torres I, Caceres C, et al. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 1999;84:421-5.
39. Crosier M, Scott D, Wilson RG, et al. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 1999;5:2682-8.
40. Engelsen IB, Stefansson IM, Beroukhim R, et al. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008;32:307-16.
41. Global analysis of differential gene expression between prostate cancer and normal prostate tissues using cDNA microarray of open-reading frame expressed sequence tags (ORESTES). Prostate Cancer Prostatic Dis 2000;3:S36.
42. Vernimmen D, Gueders M, Pisvin S, et al. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89:899-906.
43. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
44. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-7.
45. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer throughmodulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
46. Agus DB, Scher HI, Higgins B, et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999;59:4761-4.
47. Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004;60:332-7.
48. Lara PN, Jr., Chee KG, Longmate J, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004;100:2125-31.
49. Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94:980-6.
50. Legrier ME, Oudard S, Judde JG, et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007;96:269-76.
51. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43.
52. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96.